Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
KROS
KROS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest KROS ETF News Today | Earnings, Events & Price Alerts
KROS News
Keros Therapeutics Reports 2025 Financial Results and Strategic Updates
1h ago
Yahoo Finance
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
4d ago
Yahoo Finance
Keros Therapeutics Appoints Charles Newton to Board of Directors
6d ago
Yahoo Finance
Five Low Price-to-Book Stocks to Buy: AES, BorgWarner, Enersys, PG&E, Keros
Jan 02 2026
NASDAQ.COM
Zacks.com Spotlights StoneCo, General Motors, Enersys, Deutsche, and Keros
Dec 16 2025
NASDAQ.COM
Reasons to Consider Keros Therapeutics, Inc. (KROS) as a Strong Momentum Stock: Is It Time to Buy?
Dec 12 2025
NASDAQ.COM
B of A Securities Keeps Neutral Rating on Keros Therapeutics (KROS)
Nov 29 2025
NASDAQ.COM
B of A Securities Keeps Neutral Rating on Keros Therapeutics and Increases Price Target to $19
Nov 28 2025
Benzinga
Keros Therapeutics Reveals Initial Findings from Tender Offer
Nov 19 2025
Newsfilter
Keros Therapeutics Launches Tender Offer to Buy Back Up to $194.4 Million in Shares
Oct 20 2025
Newsfilter
Keros Therapeutics Launches Tender Offer to Buy Back Up to $194.4 Million in Shares
Oct 20 2025
SeekingAlpha
ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal
Aug 21 2025
Newsfilter
Keros Receives U.S. FDA Orphan Drug Designation for KER-065 in Duchenne Muscular Dystrophy Treatment
Aug 20 2025
Newsfilter
Keros Therapeutics' Treatment for Duchenne Muscular Dystrophy Receives Orphan Drug Designation from FDA
Aug 20 2025
NASDAQ.COM
Keros To Receive Milestone Payment Under License Agreement With Takeda
Jul 17 2025
NASDAQ.COM
Fat, not muscle: drugmakers in race for next weight-loss breakthrough
Jun 18 2025
Reuters
Show More News
